Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Baker

Showing results (191-200 of 1,278) with videos related to

Pageof 128
Sort By:
Immunology|December 8, 2016
Depletion of CD52-positive cells inhibits the development of central nervous system autoimmune disease, but deletes an immune-tolerance promoting CD8 T-cell population. Implications for secondary autoimmunity of alemtuzumab in multiple sclerosisStephanie von Kutzleben, Gareth Pryce, Gavin Giovannoni, et al.
Chemical Research in Toxicology|January 22, 2002
Characterization of the substrate specificity of a human 5-hydroxymethyluracil glycosylase activityDavid Baker, Pingfang Liu, Artur Burdzy, et al.
Protein Science : a Publication of the Protein Society|March 22, 2003
Structural and kinetic characterization of the simplified SH3 domain FP1Qian Yi, Ponni Rajagopal, Rachel E Klevit, et al.
Protein Science : a Publication of the Protein Society|July 29, 2010
Evaluation and ranking of enzyme designsGert Kiss, Daniela Röthlisberger, David Baker, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 26, 2004
Protein structure prediction for the male-specific region of the human Y chromosomeKrzysztof Ginalski, Leszek Rychlewski, David Baker, et al.
Multiple Sclerosis and Related Disorders|February 21, 2019
Potential mechanisms of action related to the efficacy and safety of cladribineDavid Baker, Gareth Pryce, Samuel S Herrod, et al.
Human Antibodies|June 21, 2021
Immunogenicity of biologics used in the treatment of inflammatory bowel diseaseMariam Bqain, Alex Efimov, David Baker, et al.
Multiple Sclerosis and Related Disorders|January 5, 2024
Neutropenia following immune-depletion, notably CD20 targeting, therapies in multiple sclerosisDavid Baker, Angray S Kang, Gavin Giovannoni, et al.
Protein Science : a Publication of the Protein Society|May 24, 2016
EditorialDaniel N A Bolon, David Baker, Dan S Tawfik
Proteins|November 23, 2013
Automating human intuition for protein designLucas G Nivón, Sinisa Bjelic, Chris King, et al.
Pageof 128

Showing results (191-200 of 1,278) with videos related to

Sort By:
Pageof 128
Immunology|December 8, 2016
Depletion of CD52-positive cells inhibits the development of central nervous system autoimmune disease, but deletes an immune-tolerance promoting CD8 T-cell population. Implications for secondary autoimmunity of alemtuzumab in multiple sclerosisStephanie von Kutzleben, Gareth Pryce, Gavin Giovannoni, et al.
Chemical Research in Toxicology|January 22, 2002
Characterization of the substrate specificity of a human 5-hydroxymethyluracil glycosylase activityDavid Baker, Pingfang Liu, Artur Burdzy, et al.
Protein Science : a Publication of the Protein Society|March 22, 2003
Structural and kinetic characterization of the simplified SH3 domain FP1Qian Yi, Ponni Rajagopal, Rachel E Klevit, et al.
Protein Science : a Publication of the Protein Society|July 29, 2010
Evaluation and ranking of enzyme designsGert Kiss, Daniela Röthlisberger, David Baker, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 26, 2004
Protein structure prediction for the male-specific region of the human Y chromosomeKrzysztof Ginalski, Leszek Rychlewski, David Baker, et al.
Multiple Sclerosis and Related Disorders|February 21, 2019
Potential mechanisms of action related to the efficacy and safety of cladribineDavid Baker, Gareth Pryce, Samuel S Herrod, et al.
Human Antibodies|June 21, 2021
Immunogenicity of biologics used in the treatment of inflammatory bowel diseaseMariam Bqain, Alex Efimov, David Baker, et al.
Multiple Sclerosis and Related Disorders|January 5, 2024
Neutropenia following immune-depletion, notably CD20 targeting, therapies in multiple sclerosisDavid Baker, Angray S Kang, Gavin Giovannoni, et al.
Protein Science : a Publication of the Protein Society|May 24, 2016
EditorialDaniel N A Bolon, David Baker, Dan S Tawfik
Proteins|November 23, 2013
Automating human intuition for protein designLucas G Nivón, Sinisa Bjelic, Chris King, et al.
Pageof 128